It's a single dose vaccine. Hopefully it will help to accelerate the pace of vaccination for the elderly in China.
The SAGE recommends use of the vaccine as a single (0.5ml) dose, in all age groups 18 and above.
CONVIDECIA was found to have 64% efficacy against symptomatic disease and 92% against severe COVID-19.